171 results
8-K
EX-99.1
CPRX
Catalyst Pharmaceuticals Inc
28 Feb 24
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
8:37pm
) non-cash amortization of intangible assets expense, (iv) acquired in-process research & development costs, and (v) the provision for income taxes. Non … for 2022, representing an increase of approximately 85.3% YoY.
Research and development expenses: In the fourth quarter of 2023, research and development
424B5
CPRX
Catalyst Pharmaceuticals Inc
5 Jan 24
Prospectus supplement for primary offering
5:15pm
additional drug products under development, complete the research and development required to commercialize such products, and thereafter … development, complete the research and development required to commercialize such products, and thereafter, if such products are approved
424B5
CPRX
Catalyst Pharmaceuticals Inc
4 Jan 24
Prospectus supplement for primary offering
6:24pm
if they occur;
Whether we will be able to acquire additional drug products under development, complete the research and development required … development, complete the research and development required to commercialize such products, and thereafter, if such products are approved
8-K
EX-99.1
6pg9o px7th4d
8 Nov 23
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
4:35pm
S-3ASR
cgs7tcheqy0f48 1y
8 Sep 23
Automatic shelf registration
4:31pm
8-K
EX-99.1
6qyi3iv56ff6
9 Aug 23
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
4:34pm
8-K
EX-99.1
kjd xgqkjcl
10 May 23
Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving
4:47pm
8-K/A
EX-99.2
t0kr2
10 Apr 23
Financial Statements and Exhibits
4:30pm
8-K/A
EX-99.1
r7qnegci
10 Apr 23
Financial Statements and Exhibits
4:30pm
8-K
EX-2.1
yirsc6ad uza
22 Dec 22
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
4:31pm
8-K
EX-99.1
551o gd9a7v
9 Nov 22
Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update
4:32pm